← For Researchers/Menopause/Research Sites

Menopause Research Sites

Sites currently running trials · ranked by activity

Endometriosis Long COVID ALS PTSD Sickle Cell Disease Lupus Prostate Cancer Menopause

169 sites · 175 trials · June 2026

Recruiting

Opening soon

Active · not recruiting

School of Psychology, Northumbria University

Newcastle upon Tyne · Tyne & Wear · United Kingdom

3 trials

Research explores how nutrition affects cognitive function and brain fog during perimenopause.

Northumbria UniversityNCT07648667 ↗

Multivitamin and mineral supplement for twelve weeks to reduce perimenopause symptoms and improve cognition, sleep, and mood.

Northumbria UniversityRecruitingNCT07242430 ↗

Magnesium supplementation tested to reduce hot flashes, mood swings, sleep problems, and cognitive issues in women transitioning to menopause.

Northumbria UniversityRecruitingNCT07235878 ↗

Aarhus University

Aarhus · Denmark

2 trials

Research compares muscle strength and function in pre-menopausal versus post-menopausal women to understand estrogen's role.

Mette HansenRecruitingNCT07649356 ↗

Research investigates how estrogen affects muscle growth during 12 weeks of exercise in postmenopausal women.

Mette HansenRecruitingNCT07617454 ↗

Mayo Clinic in Rochester

Rochester · Minnesota · United States

2 trials

Study examines how hot flashes in women relate to blood vessel dysfunction and cardiovascular disease risk.

Mayo ClinicRecruitingNCT05193968 ↗

AI-powered ultrasound tool to detect endometrial cancer or precancerous lesions in postmenopausal women with abnormal bleeding.

Mayo ClinicRecruitingNCT06365905 ↗

Mayo Clinic in Florida

Jacksonville · Florida · United States

2 trials

AI-powered ultrasound tool to detect endometrial cancer or precancerous lesions in postmenopausal women with abnormal bleeding.

Mayo ClinicRecruitingNCT06365905 ↗

Tirzepatide to reduce hot flashes and slow biological aging in obese postmenopausal women.

Mayo ClinicPh 4RecruitingNCT07218445 ↗

Brigham and Women's Hospital

Boston · Massachusetts · United States

2 trials

Comparison of trazodone, daridorexant, and cognitive behavioral therapy for treating insomnia in perimenopausal and postmenopausal women.

Brigham and Women's HospitalPh 4RecruitingNCT07136415 ↗

Drug elinzanetant tested to improve blood vessel health in women experiencing moderate to severe hot flashes.

Massachusetts General HospitalPh 2RecruitingNCT07077395 ↗

GSSI Bradenton

Bradenton · Florida · United States

1 trial

Study examines how hydration needs change across female life stages from reproductive years through menopause.

PepsiCo Global R&DRecruitingNCT07653620 ↗

GSSI Valhalla

Valhalla · New York · United States

1 trial

Study examines how hydration needs change across female life stages from reproductive years through menopause.

PepsiCo Global R&DRecruitingNCT07653620 ↗

Seoul National University

Seoul · Seoul · South Korea

1 trial

Trial tests combined electrical muscle stimulation and resistance training in inactive post-menopausal women aged 50-70.

Seoul National UniversityNCT07628790 ↗

Halic University

Istanbul · Turkey (Türkiye)

1 trial

Study investigates relationship between genitourinary symptoms and respiratory function in post-menopausal women.

Halic UniversityNCT07651566 ↗

Institut Català de la Salut (ICS) - Camp de Tarragona.

Tarragona · Spain

1 trial

Mixed-methods study examines how cultural background influences menopause experiences and quality of life.

Institut Investigacio Sanitaria Pere VirgiliRecruitingNCT07648680 ↗

Department of Physical Education and Sport Science, University of Thessaly

Trikala · Karies · Greece

1 trial

Study evaluates long-term metabolic, mental health, and physical performance effects of regular dance exercise.

University of ThessalyRecruitingNCT07615829 ↗

Carnegie Mellon University

Pittsburgh · Pennsylvania · United States

1 trial

Research investigates whether combining two brain stimulation techniques enhances effects better than either alone.

Carnegie Mellon UniversityNCT07635017 ↗

Mayo Clinic

Jacksonville · Florida · United States

1 trial

Trial evaluates virtual reality program effectiveness for managing menopause symptoms in women.

Mayo ClinicNCT07633743 ↗

The Ohio State University

Columbus · Ohio · United States

1 trial

Study tests lifestyle medicine and mindfulness group visits for managing perimenopause and menopause symptoms.

Ohio State UniversityNCT07619352 ↗

NIHR Southampton Clinical Research Facility

Southampton · Hampshire · United Kingdom

1 trial

A 12-week supplement containing myo-inositol, berberine, cinnamon, and chromium tests effects on body composition in women aged 38-55.

University of SouthamptonNCT07615777 ↗

Tokat Gaziosmanpasa University

Erbaa · Tokat Province · Turkey (Türkiye)

1 trial

Pecha Kucha versus PowerPoint presentation methods compared for teaching menopause knowledge and reducing myth beliefs in women.

Tokat Gaziosmanpasa UniversityNCT07623603 ↗

Esraa Fikry Massoud

Cairo · Egypt

1 trial

Sensory motor neck training investigates effects on hand grip strength in postmenopausal women with fibromyalgia neck pain.

Cairo UniversityNCT07624188 ↗

Alethios, Inc.

San Francisco · California · United States

1 trial

Salmon protein hydrolysate supplement ProGo tests effects on weight and quality of life in overweight menopausal women aged 40-65.

Hofseth Biocare ASANCT07611305 ↗

Istituto Auxologico Italiano IRCCS

Miano · Lombardy · Italy

1 trial

Study examines microRNA markers predicting treatment response to romosozumab and abaloparatide in postmenopausal women with osteoporosis.

Istituto Auxologico ItalianoRecruitingNCT07616401 ↗

IRCCS Ospedale Galeazzi Sant'Ambrogio

Milan · Lombardy · Italy

1 trial

Study examines microRNA markers predicting treatment response to romosozumab and abaloparatide in postmenopausal women with osteoporosis.

Istituto Auxologico ItalianoOpening soonNCT07616401 ↗

Fenerbahce University

Istanbul · Atasehir · Turkey (Türkiye)

1 trial

Structured combined exercise program tests effects on heart rate variability, menopausal symptoms, and quality of life in postmenopausal women.

Fenerbahce UniversityRecruitingNCT07615790 ↗

Gulbenkian Institute for Molecular Medicine, Lisbon

Lisbon · Portugal

1 trial

Study examines how gut microbiome changes relate to hormonal shifts during menopause in women aged 40-64.

Gulbenkian Institute for Molecular MedicineRecruitingNCT07614542 ↗

Ahram Canadian University

Giza · Giza Governorate · Egypt

1 trial

Trial compares traditional pulmonary rehab versus Lung Boost device for respiratory function in post-mastectomy postmenopausal women.

Ahram Canadian UniversityNCT07608042 ↗

University of Illinois, Chicago

Chicago · Illinois · United States

1 trial

Fezolinetant drug tested against placebo to assess cardiovascular and cognitive effects in women with severe menopausal hot flashes.

Rebecca ThurstonPh 3NCT07606664 ↗

University of Pittsburgh

Pittsburgh · Pennsylvania · United States

1 trial

Fezolinetant drug tested against placebo to assess cardiovascular and cognitive effects in women with severe menopausal hot flashes.

Rebecca ThurstonPh 3NCT07606664 ↗

Site CA15002

Montreal · Canada

1 trial

Observational study tracks outcomes of Canadian menopausal women prescribed fezolinetant for hot flashes in routine medical practice.

Astellas Pharma Europe Ltd.RecruitingNCT07602530 ↗

Site CA15001

Prince Albert · Canada

1 trial

Observational study tracks outcomes of Canadian menopausal women prescribed fezolinetant for hot flashes in routine medical practice.

Astellas Pharma Europe Ltd.RecruitingNCT07602530 ↗

Cuerpos Serranos S.L.

Madrid · Spain

1 trial

Study examining menopausal symptoms in Spanish women aged 40 to 70 and links to physical activity.

Cuerpos Serranos S.L.RecruitingNCT07596069 ↗

Universidad Politécnica de Madrid

Madrid · Spain

1 trial

Study examining menopausal symptoms in Spanish women aged 40 to 70 and links to physical activity.

Cuerpos Serranos S.L.RecruitingNCT07596069 ↗

University of Delaware

Newark · Delaware · United States

1 trial

Estradiol hormone treatment improves blood vessel function in women approaching menopause.

University of DelawarePh 4NCT04255160 ↗

The Center for Applied Health Sciences

Canfield · Ohio · United States

1 trial

Amylopectin chromium blend supplements support protein metabolism and glucose control in midlife women.

Nutrition 21, Inc.RecruitingNCT07402382 ↗

Site DE49001

Berlin · Germany

1 trial

Fezolinetant non-hormone tablets reduce hot flashes and night sweats in menopausal German women.

Astellas Pharma Europe Ltd.NCT07455812 ↗

Orange Coast Women's Medical Group

Laguna Hills · California · United States

1 trial

Silicone gel device StrataMGT treats vaginal dryness as effectively as estrogen cream in menopausal women.

Stratpharma AGRecruitingNCT05672901 ↗

Abba Medical Group

Miami · Florida · United States

1 trial

Silicone gel device StrataMGT treats vaginal dryness as effectively as estrogen cream in menopausal women.

Stratpharma AGRecruitingNCT05672901 ↗

One Health Research Clinic

Johns Creek · Georgia · United States

1 trial

Silicone gel device StrataMGT treats vaginal dryness as effectively as estrogen cream in menopausal women.

Stratpharma AGRecruitingNCT05672901 ↗

Sivas Cumhuriyet University

Sivas · Merkez · Turkey (Türkiye)

1 trial

Progressive relaxation exercises and education reduce menopause symptoms, stress, and anxiety in menopausal women.

Cumhuriyet UniversityNCT07412093 ↗

Universitat de Barceñpma

L'Hospitalet de Llobregat · Barcelona · Spain

1 trial

Nursing podcast and video program improves mental health and self-care in perimenopausal women.

University of BarcelonaRecruitingNCT07165964 ↗

FutureMeds Glasgow

Glasgow · Glasgow · United Kingdom

1 trial

Probiotic blend supplement reduces menopause symptoms by boosting estrogen circulation in women.

Community Pharmacology Services LtdRecruitingNCT06446869 ↗

Erevna Innovations Inc.

Montreal · Quebec · Canada

1 trial

Injectable skin fillers restore collagen and elasticity in postmenopausal women's aging skin.

Erevna Innovations Inc.Ph 4NCT07205744 ↗

University Hospital of Bern, Department of Gynecological Endocrinology & Reproductive Medicine

Bern · Switzerland

1 trial

Hormone replacement therapy and cognitive behavioral therapy treat insomnia in menopausal women.

Insel Gruppe AG, University Hospital BernPh 4RecruitingNCT06497894 ↗

Sohag University

Sohag · Egypt

1 trial

Three-dimensional ultrasound and hysteroscopy are compared for evaluating abnormal bleeding in perimenopausal women.

Sohag UniversityRecruitingNCT07309692 ↗

Bayer

Whippany · New Jersey · United States

1 trial

Observational study examines real-world usage and effectiveness of elinzanetant, a brain-signaling drug, for menopausal hot flashes.

BayerNCT07490431 ↗

Research Site

Birmingham · Alabama · United States

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Long Beach · California · United States

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Fort Myers · Florida · United States

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

St. Petersburg · Florida · United States

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Lincoln · Nebraska · United States

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Canton · Ohio · United States

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Chattanooga · Tennessee · United States

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Nashville · Tennessee · United States

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Eagle River · Wisconsin · United States

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Brasschaat · Belgium

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Charleroi · Belgium

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Ghent · Belgium

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Haine-Saint-Paul · Belgium

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Leuven · Belgium

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Libramont-Chevigny · Belgium

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Namur · Belgium

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Greenfield Park · Quebec · Canada

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Montreal · Quebec · Canada

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Paris · France

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Vandœuvre-lès-Nancy · France

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Batumi · Georgia

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Tbilisi · Georgia

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Berlin · Germany

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Düsseldorf · Germany

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Essen · Germany

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Budapest · Hungary

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Debrecen · Hungary

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Kaposvár · Hungary

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Kecskemét · Hungary

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Nyíregyháza · Hungary

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Pécs · Hungary

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Szeged · Hungary

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Jerusalem · Israel

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Nahariya · Israel

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Petah Tikva · Israel

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Bologna · Italy

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Catanzaro · Italy

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Meldola · Italy

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Messina · Italy

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Milan · Italy

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Monza · Italy

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Naples · Italy

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Roma · Italy

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Umbria · Italy

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Bydgoszcz · Poland

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Lodz · Poland

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Piła · Poland

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Rzeszów · Poland

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Skorzewo · Poland

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Warsaw · Poland

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Almada · Portugal

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Lisbon · Portugal

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Kazan' · Russia

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Krasnodar · Russia

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Kursk · Russia

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Moscow · Russia

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

Research Site

Pyatigorsk · Russia

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

100

Research Site

Ryazan · Russia

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

101

Research Site

Saint Petersburg · Russia

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

102

Research Site

Volgograd · Russia

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

103

Research Site

Goyang-si · South Korea

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

104

Research Site

Incheon · South Korea

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

105

Research Site

Barcelona · Spain

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

106

Research Site

Madrid · Spain

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

107

Research Site

Seville · Spain

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

108

Research Site

Zaragoza · Spain

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

109

Research Site

Cherkasy · Ukraine

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

110

Research Site

Chernivtsі · Ukraine

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

111

Research Site

Kyiv · Ukraine

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

112

Research Site

M. Kyiv · Ukraine

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

113

Research Site

S. Khodosivka · Ukraine

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

114

Research Site

Uzhhorod · Ukraine

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

115

Research Site

Derby · United Kingdom

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

116

Research Site

Leicester · United Kingdom

1 trial

Trial compares oral AZD9833 versus injectable fulvestrant for advanced hormone-receptor-positive breast cancer in postmenopausal women.

AstraZenecaPh 2NCT04214288 ↗

117

CaRe Clinics

Calgary · Alberta · Canada

1 trial

ABCL635 injectable drug tested for safety and effectiveness in treating moderate-to-severe hot flashes in postmenopausal women.

AbCellera Biologics Inc.Ph 1 / Ph 2NCT07118891 ↗

118

CaRe Clinics

Red Deer · Alberta · Canada

1 trial

ABCL635 injectable drug tested for safety and effectiveness in treating moderate-to-severe hot flashes in postmenopausal women.

AbCellera Biologics Inc.Ph 1 / Ph 2NCT07118891 ↗

119

Mount Saint Joseph Hospital Clinical Trials Phase 1 Unit

Vancouver · British Columbia · Canada

1 trial

ABCL635 injectable drug tested for safety and effectiveness in treating moderate-to-severe hot flashes in postmenopausal women.

AbCellera Biologics Inc.Ph 1 / Ph 2NCT07118891 ↗

120

Centricity Research

Toronto · Ontario · Canada

1 trial

ABCL635 injectable drug tested for safety and effectiveness in treating moderate-to-severe hot flashes in postmenopausal women.

AbCellera Biologics Inc.Ph 1 / Ph 2NCT07118891 ↗

121

Alpha Recherche Clinique

Lévis · Quebec · Canada

1 trial

ABCL635 injectable drug tested for safety and effectiveness in treating moderate-to-severe hot flashes in postmenopausal women.

AbCellera Biologics Inc.Ph 1 / Ph 2NCT07118891 ↗

122

GCP Research

Montreal · Quebec · Canada

1 trial

ABCL635 injectable drug tested for safety and effectiveness in treating moderate-to-severe hot flashes in postmenopausal women.

AbCellera Biologics Inc.Ph 1 / Ph 2NCT07118891 ↗

123

Altasciences Company Inc.

Mount Royal · Quebec · Canada

1 trial

ABCL635 injectable drug tested for safety and effectiveness in treating moderate-to-severe hot flashes in postmenopausal women.

AbCellera Biologics Inc.Ph 1 / Ph 2NCT07118891 ↗

124

Clinique RSF Inc.

Québec · Quebec · Canada

1 trial

ABCL635 injectable drug tested for safety and effectiveness in treating moderate-to-severe hot flashes in postmenopausal women.

AbCellera Biologics Inc.Ph 1 / Ph 2NCT07118891 ↗

125

Diex Recherche Québec

Québec · Quebec · Canada

1 trial

ABCL635 injectable drug tested for safety and effectiveness in treating moderate-to-severe hot flashes in postmenopausal women.

AbCellera Biologics Inc.Ph 1 / Ph 2NCT07118891 ↗

126

Diex Recherche Sherbrooke

Sherbrooke · Quebec · Canada

1 trial

ABCL635 injectable drug tested for safety and effectiveness in treating moderate-to-severe hot flashes in postmenopausal women.

AbCellera Biologics Inc.Ph 1 / Ph 2NCT07118891 ↗

127

Diex Recherche Trois-Rivières

Trois-Rivières · Quebec · Canada

1 trial

ABCL635 injectable drug tested for safety and effectiveness in treating moderate-to-severe hot flashes in postmenopausal women.

AbCellera Biologics Inc.Ph 1 / Ph 2NCT07118891 ↗

128

Diex Recherche Victoriaville

Victoriaville · Quebec · Canada

1 trial

ABCL635 injectable drug tested for safety and effectiveness in treating moderate-to-severe hot flashes in postmenopausal women.

AbCellera Biologics Inc.Ph 1 / Ph 2NCT07118891 ↗

129

Mayo Clinic in Arizona

Scottsdale · Arizona · United States

1 trial

AI-powered ultrasound tool to detect endometrial cancer or precancerous lesions in postmenopausal women with abnormal bleeding.

Mayo ClinicRecruitingNCT06365905 ↗

130

Henry Ford Medical Center

Novi · Michigan · United States

1 trial

Comparison of trazodone, daridorexant, and cognitive behavioral therapy for treating insomnia in perimenopausal and postmenopausal women.

Brigham and Women's HospitalPh 4RecruitingNCT07136415 ↗

131

Atrium Health Wake Forest Baptist

Winston-Salem · North Carolina · United States

1 trial

Comparison of trazodone, daridorexant, and cognitive behavioral therapy for treating insomnia in perimenopausal and postmenopausal women.

Brigham and Women's HospitalPh 4Opening soonNCT07136415 ↗

132

University of Pittsburgh Medical Center

Pittsburgh · Pennsylvania · United States

1 trial

Comparison of trazodone, daridorexant, and cognitive behavioral therapy for treating insomnia in perimenopausal and postmenopausal women.

Brigham and Women's HospitalPh 4RecruitingNCT07136415 ↗

133

University of Utah

Salt Lake City · Utah · United States

1 trial

Comparison of trazodone, daridorexant, and cognitive behavioral therapy for treating insomnia in perimenopausal and postmenopausal women.

Brigham and Women's HospitalPh 4RecruitingNCT07136415 ↗

134

University of Vienna

Vienna · State of Vienna · Austria

1 trial

Beetroot juice nitrate combined with exercise to improve blood vessel function and blood pressure in postmenopausal women.

University of ViennaRecruitingNCT06527248 ↗

135

University Hospital Bern

Bern · Switzerland

1 trial

Hormone therapy combined with GLP-1 medication to improve blood sugar control in newly postmenopausal women with diabetes.

Lia BallyRecruitingNCT06715514 ↗

136

National Institutes of Health Clinical Center

Bethesda · Maryland · United States

1 trial

Biorepository collecting ovarian tissue samples frozen before cancer or gonadotoxic treatments that risk female infertility.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)RecruitingNCT05440617 ↗

137

Rangueil Hospital

Toulouse · France · France

1 trial

Time-restricted eating with afternoon exercise to prevent muscle loss and improve blood sugar in obese postmenopausal women with diabetes.

University Hospital, ToulouseNCT07075133 ↗

138

University of Wisconsin - Madison

Madison · Wisconsin · United States

1 trial

Dairy whey protein phospholipid concentrate versus eggs as choline sources to study body choline absorption and metabolism.

University of Wisconsin, MadisonNCT06902480 ↗

139

Health Sciences Research Centre, Life Sciences Department, University of Roehampton

London · UK · United Kingdom

1 trial

Prebiotic gut health drink tested to improve blood sugar control and reduce diabetes risk in postmenopausal women.

University of RoehamptonNCT07565675 ↗

140

31788 Alabama CRS

Birmingham · Alabama · United States

1 trial

Hormone therapy tested to reduce severe hot flashes and night sweats in women living with HIV.